Main Presentation: “The Endothelial Glycocalyx: From Hemodynamic Hypothesis To Clinical Risk Predictor” by Hans Vink, PhD
July 2nd, 2025 @ 10 am PST
The endothelial glycocalyx is essential for microvascular health, and that identification of glycocalyx damage can identify (early) cardiovascular risk in patients and healthy individuals. This is based on over four decades of research on the glycocalyx. Recant development of specific glycocalyx therapeutics show great potential for improvement of microvascular health Ongoing clinical trials are currently testing its potential impact on cardiovascular risk in a variety of clinical conditions.
Join Zoom Meeting
Meeting ID: 896 8440 5726
Passcode: 164422
—
One tap mobile
+16694449171,,81361922664#,,,,*010741# US
+16699006833,,81361922664#,,,,*010741# US (San Jose)
—
Dial by your location
• +1 669 444 9171 US
• +1 669 900 6833 US (San Jose)
• +1 253 205 0468 US
• +1 253 215 8782 US (Tacoma)
• +1 346 248 7799 US (Houston)
• +1 719 359 4580 US
• +1 301 715 8592 US (Washington DC)
• +1 305 224 1968 US
• +1 309 205 3325 US
• +1 312 626 6799 US (Chicago)
• +1 360 209 5623 US
• +1 386 347 5053 US
• +1 507 473 4847 US
• +1 564 217 2000 US
• +1 646 931 3860 US
• +1 689 278 1000 US
• +1 929 436 2866 US (New York)
Meeting ID: 896 8440 5726
Passcode: 164422
Find your local number:
About Hans Vink, PhD
Hans Vink received his physics degree in 1989 at the University of Amsterdam. After receiving his PhD in Medicine in 1994 and a post-doctoral fellowship at the dept. Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, USA, he returned to the University of Amsterdam and developed a research program on the endothelial glycocalyx, supported by grants from the Netherlands Organization for Scientific Research (NWO 1997 – 1999) and a fellowship from the Royal Netherlands Academy of Sciences (KNAW 2000 – 2005). In 2006 he was awarded an Established Investigatorship by the Netherlands Heart Foundation and moved to the University of Maastricht as a Principal Investigator at the Cardiovascular Research Institute of Maastricht, and he was appointed professor of Circulatory Physics at the University in Amsterdam in 2008. His research on the endothelial glycocalyx progresses towards clinically applicable tools for early diagnosis of cardiovascular risk and new therapeutic approaches to protect the vascular wall against atherogenic challenges and is supported by program grants from the Center for Translational Molecular Medicine, The Netherlands Heart Foundation, The Dutch Diabetes Research Foundation and the Netherlands Kidney Foundation. He founded several companies such as GlycoCheck BV, GlycoCheck US and the GlycoCalyx Research Institute (www.glycocalyx.com) for development of a non-invasive biomedical device to measure the health of the endothelial glycocalyx (the GlycoCheck device) and several glycocalyx specific therapeutics. He has published more than 100 scientific publications and supervised 10 PhD projects .